摘要
自身造血干细胞移植术后霍奇金淋巴瘤的复发率约为50%。复发通常发生在手术一年后,而且治疗起来并不容易。复发霍奇金淋巴瘤的自然病程可从刚开始的快速发展逐渐过渡到一个相对顽固且不活跃的缓解期。如果患者年轻,无伴发疾病且肿瘤对化疗敏感,则仍然有希望治愈。治疗方案的选择取决于一系列临床因素(如复发时间,对细胞毒疗法的敏感性以及疾病所处的阶段等)。放疗前对病史的要求:通过临床试验发现有HLA相合供体和新的因子。虽然很少有病例能获得治愈,但一系列研究结果表明,放疗、单药或联合化疗和强度减低的同种移植对病情的控制具有极好的效果。本文针对这些方法的治疗效果进行分析,并对病例收治标准、试验药以及治疗方案进行了讨论。
Recurrence of Hodgkin lymphoma （HL） occurs about 50% of patients after autologous stem cell transplantation （ ASCT）, usually within the first year and represents a significant therapeutic challenge. The natural history of recurrent HL may range from a rapidly progressive to a more indolent course ： if patients are young without comorbidities and able to tolerate additional therapies, expectations are often still high. The approach of treatment depends on clinical variables （ time to relapse, perceived sensitivity to additional cytotoxie therapy, disease stage ）. Prior history of radiation therapy： the availability of an HLAidentical donor and the availability of new agents via clinical trial. Although very few of these patients can be cured, results from reported series demonstrated that excellent disease control can be achieved with radiation, single or multiple agent chemotherapy, and reduced-intensity allogeneic transplantation. The results of these approaches were reviewed. A treatment standard, investigational agents and approaches were discussed.
出处
《实用医院临床杂志》
2010年第3期24-26,共3页
Practical Journal of Clinical Medicine
关键词
治疗
自身造血干细胞移植术后复发霍杰金淋巴瘤
Management
Recurrence of Hodgkin lymphoma after autologous stem cell transplant
